DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 064008
NDA 064008 describes PENTACEF, which is a drug marketed by Glaxosmithkline and is included in three NDAs. Additional details are available on the PENTACEF profile page.
The generic ingredient in PENTACEF is ceftazidime. There are seventeen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the ceftazidime profile page.
The generic ingredient in PENTACEF is ceftazidime. There are seventeen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the ceftazidime profile page.
Summary for 064008
| Tradename: | PENTACEF |
| Applicant: | Glaxosmithkline |
| Ingredient: | ceftazidime |
| Patents: | 0 |
| Therapeutic Class: | Antibacterials |
| Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 064008
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 6GM/VIAL | ||||
| Approval Date: | Mar 31, 1992 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 10GM/VIAL | ||||
| Approval Date: | Mar 31, 1992 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
